Longbow Capital

Clir Renewables Inc. is a company that specializes in cloud-based renewable energy asset management and reporting software. Founded in 2016 and headquartered in Vancouver, Canada, with an additional office in Glasgow, United Kingdom, Clir's software-as-a-service platform is designed to assist asset managers and owners in optimizing the performance and profitability of renewable energy plants. By integrating deep domain expertise with artificial intelligence, Clir’s platform enhances annual energy production, monitors asset health, and effectively manages financial and technical risks associated with renewable energy assets.

VoltaGrid LLC, incorporated in 2020 and based in Bellaire, Texas, operates in the energy sector with a focus on advanced energy management and generation solutions. The company offers a portable and scalable power platform that integrates natural gas and grid power, aimed at enhancing power quality and reliability. Its innovative approach is designed to support industries such as pressure pumping, remote mining, utility, and distributed generation, enabling clients to achieve significant reductions in emissions and fuel consumption. By leveraging intelligent technology, VoltaGrid is poised to transform mobile power generation and contribute to a more sustainable energy landscape.

Domainex Ltd. is a biotechnology company based in Saffron Walden, United Kingdom, that specializes in contract research and manufacturing services focused on drug discovery. Established in 2001, the company provides a comprehensive range of services, including medicinal and computational chemistry, protein expression and purification, biochemical assay development, and DMPK analysis. Domainex is known for its expertise in developing advanced medicines through innovative technologies, including biochemical binding techniques, particularly for oncology drugs and treatments for inflammatory diseases. The company has a significant emphasis on hit identification and candidate drug synthesis, utilizing both virtual and fragment-based approaches to address complex drug discovery challenges. In 2007, Domainex merged with NCE Discovery, enhancing its capabilities in both biological and chemical research.